Acurx Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
ACXP$1.060.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| | | | | | | |
|---|---|---|---|---|---|---|
| | Years Ended | |||||
| · · December 31, | ||||||
| | 2023 | 2022 | ||||
| | | | | | | |
| OPERATING EXPENSES · · | ||||||
| Research and Development | | $6,043,597 | | $4,754,271 | ||
| General and Administrative | | 8,534,171 | | 7,338,505 | ||
| | | | | | | |
| TOTAL OPERATING EXPENSES | | 14,577,768 | | 12,092,776 | ||
| | | | | | | |
| NET LOSS | | $(14,577,768) | | $(12,092,776) | ||
| | | | | | | |
| LOSS PER SHARE | | | ||||
| Basic and diluted net loss per common share | | $(1.15) | | $(1.12) | ||
| | | | | | | |
| Weighted average common shares outstanding, basic and diluted | | 12,671,572 | | 10,816,412 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.